IKCS 2021: A phase 3 trial of lenvatinib plus pembrolizumab versus sunitinib as a first-line treatment for patients with advanced renal cell carcinoma: overall survival follow-up analysis (CLEAR study).

Non ancora tradotto Non ancora tradotto
Autori
Categoria Primary study
Conference2021 International Kidney Cancer Symposium; November 5-6
Year 2021
Questo articolo non ha abstract
Epistemonikos ID: 67beca08066455e257faaead193561646e37ae4b
First added on: May 09, 2025